Phase 3 trial in China successfully confirms ACARIZAX® safety and efficacy in patients with house dust mite allergy
Go back to Phase 3 trial in China successfully confirms ACARIZAX® safety and efficacy in patients with house dust mite allergy| ALASKA AIR GROUP, Inc. (NYSE: ALK) | Delayed: 33.54 -0.82 (2.39%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.36 | 52 Week High | $87.17 | |||
| Open | $33.84 | 52 Week Low | $54.51 | |||
| Day High | $35.86 | P/E | 4.68 | |||
| Day Low | $33.20 | EPS | $7.16 | |||
| Volume | 11,456,978 | |||||



